BPC-157 amino acids — Pro Peptide Strip
Fifteen residues identify the molecule. The research then moves from that sequence to vessels, gastric tissue and the load a repaired tendon can bear.
What amino acids are in BPC-157?
BPC-157’s sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. In full, that is glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine and valine. Pentadecapeptide simply means a peptide with fifteen amino acids. The synthetic molecule copies part of a protein found in human gastric juice.
The consecutive prolines give this strip of amino acids a recognizable pattern. For me the sequence comes first: a paper can only tell us about the material it studied. The BPC-157 name appears in the research below; searches shortened to BP157 still need that precise identity. PL 14736, PLD-116, PL-10 and Bepecin are other research designations in its history.
Tendon function after a cut
The transected rat Achilles tendon study tested more than appearances. BPC-157 improved biomechanical and functional recovery alongside microscopic and macroscopic findings, with better collagen organization and tendon integrity than untreated controls. Rat tendocytes, the cells associated with tendon, also showed outgrowth in culture.
Function gets my closest attention in that experiment. An advancing sheet of cells and an organized tissue sample are encouraging stages; a tendon also has to carry force. This experiment followed several kinds of recovery in rats. Human injury recovery still needs controlled clinical evidence.
Gastric ulcers and VEGFR2
In Wistar rats with gastric ulcers, BPC-157 reduced ulcer area and accelerated healing, including rebuilding of glandular epithelium and granulation tissue. The gastric origin of the sequence makes that result an understandable starting territory. The tendon work asks a different tissue to repair.
A possible connection is angiogenesis, the growth of new blood vessels. VEGFR2 research in human vascular endothelial cells, chick membranes and rat hindlimb ischemia found increased receptor expression and internalization, followed by downstream Akt-eNOS signaling. Vessel density and blood-flow recovery improved in the experimental models; blocking receptor internalization blocked the effect. I appreciate that attempt to interrupt the mechanism, while leaving the human-benefit question for human trials.
BPC-157 clearance and human data
Formal pharmacokinetic work in rats and beagle dogs found an elimination half-life under 30 minutes and rapid breakdown into smaller fragments that enter normal amino-acid metabolism. Those are animal measurements of what happens to the molecule. They establish no human recovery timetable or dosing schedule.
The 2025 intravenous safety pilot in two healthy adults reported no observed adverse events and no measurable cardiac, hepatic, renal, thyroid or glucose biomarker changes. A 2025 narrative review described only three small human pilots overall, no rigorous large-scale trials, and a foundational literature concentrated in one research group. I read the broad animal findings with interest and the tiny human denominator with considerable restraint.
BPC-157 research integrity and status
Correct amino acids are the beginning of research integrity. Unregulated material introduces uncertainty about identity, purity and actual content, a concern discussed in the BPC-157 narrative review. A printed peptide name cannot establish that a preparation matches the molecule in a study.
BPC-157 has no FDA approval and is prohibited in sport at all times under WADA S0. On FDA’s page current as of April 22, 2026, BPC-157 appears among bulk substances whose nominations were withdrawn. The safety concerns remain on record; withdrawal confers neither FDA approval nor Category 1 status. Long-term human safety remains unknown. Wolverine and KLOW both include BPC-157, carrying the single-component evidence into combinations that still lack controlled testing.